<p>諾和諾德 A/V NYSE: NVO 股票正在考驗買入持有投資者的耐心。在過去五年中，NVO 股票上漲超過 200%。然而，在過去一年中，它下跌超過 61%，在 2025 年下跌超過 43%。即使在波動的醫療股票領域，這種表現不佳也無法被忽視。</p>
<p>但目前讓股東感到焦慮的是公司最近下調了全年指引，這導致股票在不到一週的時間內下跌了 3%。</p>
<p>獲取 <strong>Novo Nordisk A/S</strong> 的提醒：</p>
<p>諾和諾德將其銷售增長預期下調至 8% 到 14% 的區間。該區間的高端現在與之前 13% 到 21% 的指引的低端一致。公司修訂後的營業利潤指引也出現類似情況，現在在 10% 到 16% 的區間內，低於之前的 16% 到 24%。</p>
<p>然而，增長即便減少仍然是增長，在許多股票似乎被高估的時刻，NVO 股票並沒有被高估。不過，長期投資者是否該拋售 NVO 股票呢？</p>
<h2>新任 CEO 面臨熟悉的問題</h2>
<p>諾和諾德最近宣佈任命新首席執行官（CEO）Maziar Mike Doustdar，他將在 8 月 6 日正式接任。Doustdar 面臨的第一個問題是 <strong>複合 GLP-1 藥物的持續威脅</strong>，這些藥物正在侵蝕公司的市場份額和增長。這在 Hims &amp; Hers Health Inc. NYSE: HIMS 在 2025 年的激增中尤為明顯。</p>
<p>雖然複合 GLP-1 藥物無疑是公司增長的問題，但並不是唯一的問題。諾和諾德還提到國際市場的 “滲透率低於預期” 和來自 Eli Lilly &amp; Co. NYSE: LLY 的競爭，該公司在臨牀療效和市場份額上持續取得進展。</p>
<h2>顯著的減重是有代價的</h2>
<p>複合 GLP-1 藥物並不是一個新問題。諾和諾德和 Eli Lilly 自推出 GLP-1 藥物以來幾乎一直面臨這個問題。</p>
<p>主要問題是成本。大多數保險公司會覆蓋 Ozempic（諾和諾德）和 Mounjaro（Eli Lilly）。這些藥物被批准用於治療 1 型糖尿病（T1D），特別是血糖控制。由於糖尿病是一種慢性疾病，保險公司將這些藥物視為符合明確的護理標準。</p>
<p>Wegovy 和 Zepbound 的保險覆蓋則不那麼一致，這兩種藥物是公司針對肥胖的 GLP-1 藥物。一個更顯著的危險是 Medicare 不覆蓋這些藥物。</p>
<p>沒有保險覆蓋，這些藥物可能會讓患者承擔高昂的費用，這使得複合 GLP-1 藥物成為尋求這些藥物好處的患者的替代選擇。通常，複合 GLP-1 藥物的價格可以比品牌產品低 <strong>50%-70%</strong>。</p>
<p>然而，另一個問題是複合藥物為何會出現在市場上。由於這些藥物在一個超出預期的可尋址市場中的壓倒性受歡迎程度，超出了諾和諾德或 Eli Lilly 的承受能力。</p>
<p>這使得食品藥品監督管理局（FDA）宣佈短缺，允許在某些條件下合法複合 GLP-1 藥物。然而，這與 FDA 批准並不相同——這是諾和諾德強調的一個區別。複合版本存在風險，其中許多風險仍然難以量化。</p>
<p>諾和諾德已提起九起訴訟，試圖阻止複合替代品的增長，但到目前為止，公司並沒有看到任何影響，儘管 FDA 已告知藥品製造商停止生產複合產品，因為 Wegovy 等產品的短缺已經結束。</p>
<h2>盈利將是下一個上漲或下跌的關鍵</h2>
<p>無論投資者站在哪一方，獲得更多的清晰度不會太久。<strong>諾和諾德將在 8 月 6 日市場開盤前公佈財報</strong>。財報應該能回答一個簡單的問題，過去 30 天股票下跌超過 29%，過去一週下跌超過 3%。</p>
<p>拋售是否過度？</p>
<p>如果公司的業績超出預期或與其預測相符，投資者可能會有一個 <strong>買入機會</strong>。NVO 股票目前的交易價格約為未來收益的 12 倍，並且相較於其歷史平均水平存在折扣。</p>
<p>這也使其相較於行業平均水平略有折扣。</p>
<p>在這樣的拋售中，容易忽視基本面。然而，諾和諾德仍然是一家非常盈利的公司，年復一年（YOY）收入和盈利均在增長。</p>
<p>投資者還應記住，Ozempic 和 Wegovy 的市場巨大，這將為許多公司提供競爭空間。</p>
<p>然而，在短期內，公司和投資者需要克服短期障礙。NVO 股票的交易價格遠低於其 50 日簡單移動平均線（SMA），這已經成為股票的阻力區域。然而，賣出量似乎正在減弱，且相對強弱指數（RSI）顯示超賣狀態，<strong>底部可能正在形成</strong>。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20250804114947_nvo841.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20250804114947_nvo841.png"/></p>
<h2>你現在應該投資 1,000 美元在諾和諾德 A/S 嗎？</h2>
<p>在考慮諾和諾德 A/S 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而諾和諾德 A/S 並不在名單上。</p>
<p>雖然諾和諾德 A/S 目前在分析師中獲得持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票的詳情</p>

諾和諾德公司

<p>諾和諾德公司的股票在 2025 年下跌超過 43%，過去一年下降了 61%，這主要歸因於疲軟的業績指引和來自 GLP-1 藥物的競爭。該公司將銷售增長預期修訂為 8%-14%，運營利潤預期為 10%-16%。新任首席執行官 Maziar Mike Doustdar 面臨來自複合 GLP-1 藥物和禮來公司的競爭挑戰。財報將於 8 月 6 日公佈，這可能會澄清股票的未來方向。目前，儘管諾和諾德是一家盈利能力強且市場潛力巨大的公司，其股票仍以折扣價交易</p>

<p>Novo Nordisk A/V NYSE: NVO stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than 43% in 2025. Even in the volatile medical stocks sector, that kind of underperformance can’t be overlooked.</p>
<div class="lb-trans"><p>諾和諾德 A/V NYSE: NVO 股票正在考驗買入持有投資者的耐心。在過去五年中，NVO 股票上漲超過 200%。然而，在過去一年中，它下跌超過 61%，在 2025 年下跌超過 43%。即使在波動的醫療股票領域，這種表現不佳也無法被忽視。</p>
</div><p>But what’s making shareholders anxious right now is the company’s recent slash of full-year guidance, which caused the stock to drop by 3% in less than a week.</p>
<div class="lb-trans"><p>但目前讓股東感到焦慮的是公司最近下調了全年指引，這導致股票在不到一週的時間內下跌了 3%。</p>
</div><p>Get <strong>Novo Nordisk A/S</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Novo Nordisk A/S</strong> 的提醒：</p>
</div><p>Novo Nordisk cut its sales growth expectations to a range of 8% and 14%. The high end of that range is now consistent with the low end of the previous guidance of 13% to 21%. A similar story emerged with the company’s revised guidance for operating profit, which is now in a range of 10% to 16%, down from 16% to 24%.</p>
<div class="lb-trans"><p>諾和諾德將其銷售增長預期下調至 8% 到 14% 的區間。該區間的高端現在與之前 13% 到 21% 的指引的低端一致。公司修訂後的營業利潤指引也出現類似情況，現在在 10% 到 16% 的區間內，低於之前的 16% 到 24%。</p>
</div><p>However, less growth is still growth, and at a time when many stocks seem overvalued, NVO stock does not. Still, is it time for long-term investors to shed NVO stock?</p>
<div class="lb-trans"><p>然而，增長即便減少仍然是增長，在許多股票似乎被高估的時刻，NVO 股票並沒有被高估。不過，長期投資者是否該拋售 NVO 股票呢？</p>
</div><h2>A New CEO Faces a Familiar Problem</h2>
<div class="lb-trans"><h2>新任 CEO 面臨熟悉的問題</h2>
</div><p>Novo Nordisk recently announced the appointment of a new chief executive officer (CEO), Maziar Mike Doustdar, who officially takes the reins on August 6. One of the first problems Doustdar faces is the <strong>continuing threat from compounded GLP-1 drugs</strong> that are eating away at the company’s market share and growth. This is particularly evident in the surge in Hims &amp; Hers Health Inc. NYSE: HIMS in 2025.</p>
<div class="lb-trans"><p>諾和諾德最近宣佈任命新首席執行官（CEO）Maziar Mike Doustdar，他將在 8 月 6 日正式接任。Doustdar 面臨的第一個問題是 <strong>複合 GLP-1 藥物的持續威脅</strong>，這些藥物正在侵蝕公司的市場份額和增長。這在 Hims &amp; Hers Health Inc. NYSE: HIMS 在 2025 年的激增中尤為明顯。</p>
</div><p>While compounded GLP-1s are undoubtedly an issue for the company's growth, they're not the only issue. Novo Nordisk also cited “lower-than-expected penetration” in international markets and the competition from Eli Lilly &amp; Co. NYSE: LLY, which continues to make gains in clinical efficacy and market share.</p>
<div class="lb-trans"><p>雖然複合 GLP-1 藥物無疑是公司增長的問題，但並不是唯一的問題。諾和諾德還提到國際市場的 “滲透率低於預期” 和來自 Eli Lilly &amp; Co. NYSE: LLY 的競爭，該公司在臨牀療效和市場份額上持續取得進展。</p>
</div><h2>Significant Weight Loss Comes at a Price</h2>
<div class="lb-trans"><h2>顯著的減重是有代價的</h2>
</div><p>Compounded GLP-1 drugs aren’t a new problem. Novo Nordisk and Eli Lilly have been facing this issue almost since they launched their GLP-1 drugs.</p>
<div class="lb-trans"><p>複合 GLP-1 藥物並不是一個新問題。諾和諾德和 Eli Lilly 自推出 GLP-1 藥物以來幾乎一直面臨這個問題。</p>
</div><p>The primary issue is cost. Most insurance companies will cover Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly). These drugs are approved for the treatment of Type-1 diabetes (T1D), specifically glycemic control. Since diabetes is a chronic condition, insurers view these drugs as consistent with clear standards of care.</p>
<div class="lb-trans"><p>主要問題是成本。大多數保險公司會覆蓋 Ozempic（諾和諾德）和 Mounjaro（Eli Lilly）。這些藥物被批准用於治療 1 型糖尿病（T1D），特別是血糖控制。由於糖尿病是一種慢性疾病，保險公司將這些藥物視為符合明確的護理標準。</p>
</div><p>Insurance coverage is less consistent for Wegovy and Zepbound, which are the companies’ respective GLP-1 drugs for obesity. A more prominent danger is that Medicare does not cover these drugs.</p>
<div class="lb-trans"><p>Wegovy 和 Zepbound 的保險覆蓋則不那麼一致，這兩種藥物是公司針對肥胖的 GLP-1 藥物。一個更顯著的危險是 Medicare 不覆蓋這些藥物。</p>
</div><p>Without insurance coverage, these drugs can be cost-prohibitive, which makes compounded GLP-1 drugs an alternative for patients looking for the benefits of these drugs. Frequently, compounded GLP-1 drugs can be obtained for <strong>50%-70% less than the branded products</strong>.</p>
<div class="lb-trans"><p>沒有保險覆蓋，這些藥物可能會讓患者承擔高昂的費用，這使得複合 GLP-1 藥物成為尋求這些藥物好處的患者的替代選擇。通常，複合 GLP-1 藥物的價格可以比品牌產品低 <strong>50%-70%</strong>。</p>
</div><p>However, another issue is why the compounded drugs are on the market to begin with. The overwhelming popularity of these drugs in a larger-than-expected addressable market was greater than Novo Nordisk or Eli Lilly could handle.</p>
<div class="lb-trans"><p>然而，另一個問題是複合藥物為何會出現在市場上。由於這些藥物在一個超出預期的可尋址市場中的壓倒性受歡迎程度，超出了諾和諾德或 Eli Lilly 的承受能力。</p>
</div><p>That allowed the Food &amp; Drug Administration (FDA) to declare a shortage, permitting the legal compounding of GLP-1 drugs under certain conditions. However, this is not the same as FDA approval—a distinction Novo Nordisk emphasizes. Compounded versions carry risks, many of which remain hard to quantify.</p>
<div class="lb-trans"><p>這使得食品藥品監督管理局（FDA）宣佈短缺，允許在某些條件下合法複合 GLP-1 藥物。然而，這與 FDA 批准並不相同——這是諾和諾德強調的一個區別。複合版本存在風險，其中許多風險仍然難以量化。</p>
</div><p>Novo Nordisk has filed nine lawsuits to try to stop the growth of compounded alternatives, but so far, the company is not seeing any impact, even though the FDA told drug makers to stop producing their compounded products now that the shortage of products like Wegovy has ended.</p>
<div class="lb-trans"><p>諾和諾德已提起九起訴訟，試圖阻止複合替代品的增長，但到目前為止，公司並沒有看到任何影響，儘管 FDA 已告知藥品製造商停止生產複合產品，因為 Wegovy 等產品的短缺已經結束。</p>
</div><h2>Earnings Will Be the Next Leg Up or Down</h2>
<div class="lb-trans"><h2>盈利將是下一個上漲或下跌的關鍵</h2>
</div><p>Whatever side of the debate investors stand on, it won’t be long until they get more clarity. <strong>Novo Nordisk reports earnings on August 6</strong> before the market opens. The earnings report should answer a simple question, with the stock down more than 29% in the last 30 days and over 3% in the last week.</p>
<div class="lb-trans"><p>無論投資者站在哪一方，獲得更多的清晰度不會太久。<strong>諾和諾德將在 8 月 6 日市場開盤前公佈財報</strong>。財報應該能回答一個簡單的問題，過去 30 天股票下跌超過 29%，過去一週下跌超過 3%。</p>
</div><p>Is the sell-off overdone?</p>
<div class="lb-trans"><p>拋售是否過度？</p>
</div><p>If the company's results exceed expectations or are just in line with their forecast, investors might have a <strong>buying opportunity</strong>. NVO stock is now trading around 12x forward earnings and is trading at a discount to its historical averages.</p>
<div class="lb-trans"><p>如果公司的業績超出預期或與其預測相符，投資者可能會有一個 <strong>買入機會</strong>。NVO 股票目前的交易價格約為未來收益的 12 倍，並且相較於其歷史平均水平存在折扣。</p>
</div><p>That also puts it at a slight discount to the sector average.</p>
<div class="lb-trans"><p>這也使其相較於行業平均水平略有折扣。</p>
</div><p>During sell-offs like this, it’s easy to overlook fundamentals. However, Novo Nordisk is still a very profitable company, increasing revenue and earnings year-over-year (YOY).</p>
<div class="lb-trans"><p>在這樣的拋售中，容易忽視基本面。然而，諾和諾德仍然是一家非常盈利的公司，年復一年（YOY）收入和盈利均在增長。</p>
</div><p>Investors should also remember that the market for Ozempic and Wegovy is massive, which will allow room for many companies to compete.</p>
<div class="lb-trans"><p>投資者還應記住，Ozempic 和 Wegovy 的市場巨大，這將為許多公司提供競爭空間。</p>
</div><p>However, in the near term, the company and investors will need to work through short-term obstacles. NVO stock is trading well below its 50-day simple moving average (SMA), which has already been an area of resistance for the stock. However, the selling volume appears to be tapering off, and with an RSI indicating oversold conditions, <strong>a bottom may be forming</strong>.</p>
<div class="lb-trans"><p>然而，在短期內，公司和投資者需要克服短期障礙。NVO 股票的交易價格遠低於其 50 日簡單移動平均線（SMA），這已經成為股票的阻力區域。然而，賣出量似乎正在減弱，且相對強弱指數（RSI）顯示超賣狀態，<strong>底部可能正在形成</strong>。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20250804114947_nvo841.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20250804114947_nvo841.png"/></p>
<h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在諾和諾德 A/S 嗎？</h2>
</div><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮諾和諾德 A/S 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而諾和諾德 A/S 並不在名單上。</p>
</div><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然諾和諾德 A/S 目前在分析師中獲得持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票的詳情</p>
</div>

諾和諾德公司的股票下跌——底部是否終於出現了？